Swiss medical device manufacturer Ypsomed AG has announced a $248 million investment to establish its first manufacturing facility in the United States, marking a major milestone in the company’s international expansion strategy. The new site will be located in Holly Springs, North Carolina, within the state’s Research Triangle region, a well-established U.S. hub for life sciences manufacturing and innovation.
According to Ypsomed, the new facility will produce self-injection systems for global biopharmaceutical partners and strengthen the company’s supply capability for the North American market. The 15,000-square-meter (approximately 160,000-square-foot) site will initially employ around 100 people, with plans to double its workforce as production scales up. Manufacturing operations are slated to begin by late 2027.
Ypsomed CEO Simon Michel said Holly Springs was selected for its close proximity to customers, skilled workforce, and strong academic infrastructure. The company cited the region’s collaborative business environment and advanced logistics network as key factors in its decision.
The North Carolina investment complements Ypsomed’s broader global growth program, which includes new facilities in Changzhou, China, and Schwerin, Germany, along with major upgrades at existing sites in Solothurn and Burgdorf, Switzerland. Altogether, the company plans to invest several hundred million Swiss francs in capacity expansion and modernization efforts worldwide over the coming years.